Current partner codePEPTIDESDE
NCT07121153·Phase 1·INTERVENTIONAL

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

Status

Completed

Phase

Phase 1

Enrollment

36

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2. The aim of the study is to see how safe the study medicine is and how it behaves in human body. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors but has previously been tested in humans. This study will last for up to 53 days.

Interventions

Treatment arms and agents.

DRUG

NNC0487-0111 A

Participants will receive single dose (level 1, level 2, level 3) injection of NNC0487-0111 A subcutaneoulsy.

DRUG

Placebo A

Participants will receive single dose (level 1, level 2, level 3) injection of placebo A subcutaneoulsy.

Timeline

From registration to results.

  1. First posted

    Aug 13, 2025

  2. Study start

    Aug 11, 2025

  3. Primary completion

    Dec 20, 2025

  4. Study completion

    Dec 20, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Feb 17, 2026

Outcomes

What the study measures.

Primary outcomes

Number of treatment emergent adverse events (TEAEs)

Time frame · From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)

Number of events

Secondary outcomes

AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose

Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)

h\*nmol/L

Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose

Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)

nmol/L

tmax,SD; the time of maximum plasma concentration of NNC0487-0111 after a single dose

Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)

h

t1/2,SD; the terminal half-life of NNC0487-0111 after a single dose

Time frame · From pre-dose on Day 1 until completion of the end of study visit (Day 23)

h

Relative change in body weight

Time frame · From baseline Day 1 until completion of the end of study visit (Day 23)

Change in fasting plasma glucose

Time frame · From baseline Day 1 until completion of the end of study visit (Day 23)

mmol/L

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
55 Years
Sex
MALE
Healthy volunteers
No

Inclusion Criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent. 3. Body mass index between 24.0 and 34.9 kg/m2 (both inclusive) at screening. Overweight and obesity should be due to excess adipose tissue, as judged by the investigator, with a body weight (more than or equal to) ≥ 65.0 kg at screening. 4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: 1. Any condition, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. 2. HbA1c ≥ 6.5 percent (%) \[48 milimol per mole (mmol/mol)\] at screening. 3. Any laboratory safety parameters at screening outside the below laboratory ranges: * Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 nanogram per mililiter (ng/mL) \[30 nanometer (nM)\] at screening * Parathyroid hormone (PTH) outside normal range at screening * Total calcium outside normal range at screening * Amylase ≥ 2 times upper limit of normal at screening * Lipase ≥ 2 times upper limit of normal at screening * Calcitonin ≥ 50 picogram per mililiter (pg/mL) at screening

Study locations

1 registered sites.

China. Showing up to 24 locations stored in the fast local snapshot.

Jinan Central Hospital

Jinan, Shandong, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Amycretin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.